DNLI - Denali Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

DNLI is currently covered by 11 analysts with an average price target of $27.64. This is a potential upside of $13.11 (90.23%) from yesterday's end of day stock price of $14.53.

Denali Therapeutics's activity chart (see below) currently has 92 price targets and 103 ratings on display. The stock rating distribution of DNLI is 95% BUY and 5% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 43.15% with an average time for these price targets to be met of 91.42 days.

Highest price target for DNLI is $45, Lowest price target is $24, average price target is $34.33.

Most recent stock forecast was given by LAURA CHICO from WEDBUSH on 06-May-2025. First documented stock forecast 01-Jan-2018.

Currently out of the existing stock ratings of DNLI, 38 are a BUY (95%), 2 are a HOLD (5%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$30

$15.48 (106.61%)

$27

2 months 11 days ago
(06-May-2025)

13/17 (76.47%)

$15.68 (109.50%)

105

Buy

$32

$17.48 (120.39%)

$87

2 months 11 days ago
(06-May-2025)

4/21 (19.05%)

$17.68 (123.46%)

111

Buy

$33

$18.48 (127.27%)

$41

4 months 11 days ago
(06-Mar-2025)

3/9 (33.33%)

$16.73 (102.83%)

382

Buy

$42

$27.48 (189.26%)

$68

4 months 15 days ago
(02-Mar-2025)

0/4 (0%)

$25.44 (153.62%)

Buy

$31

$16.48 (113.50%)

$32

5 months 7 days ago
(10-Feb-2025)

0/3 (0%)

$10.42 (50.63%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is DNLI (Denali Therapeutics) average time for price targets to be met?

On average it took 91.42 days on average for the stock forecasts to be realized with a an average price target met ratio 43.15

Which analyst has the current highest performing score on DNLI (Denali Therapeutics) with a proven track record?

MICHAEL YEE

Which analyst has the most public recommendations on DNLI (Denali Therapeutics)?

Michael Yee works at JEFFERIES and has 12 price targets and 8 ratings on DNLI

Which analyst is the currently most bullish on DNLI (Denali Therapeutics)?

Michael Yee with highest potential upside - $30.48

Which analyst is the currently most reserved on DNLI (Denali Therapeutics)?

Charles Duncan with lowest potential downside - -$0

Denali Therapeutics in the News

William Blair reiterates Outperform rating on Denali stock after BLA acceptance

Investing.com – William Blair has reiterated its Outperform rating on Denali Therapeutics Inc. (NASDAQ:DNLI) following the Biologics License Application (BLA) acceptance and priority review for the company’s Hunter syndrome treatment. The company, currently trading at $14.53, has received strong analyst support, with a consensus recommendation of 1.21 (Strong Buy) and price targets ranging from $24...

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

Denali Therapeutics Inc. FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval Tividenofusp alfa is designed to deliver missing enzyme to entire body and cross blood-brain barrier into the brain Tividenofusp alfa leads company’s broader TransportVehicle™-enabled pipeline SOUTH SAN FRANCISCO, Calif., July 07, 2025 (GLOBE NEWSWIRE) — Denali Therapeutics...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?